New chemotherapies in breast cancer-Reference-Cited by-同舟云学术

New chemotherapies in breast cancer

Published:2017-08-22 Issue:3 Volume:10 Page:127-131
ISSN:1865-5041
Container-title:memo - Magazine of European Medical Oncology
language:en
Short-container-title:memo

Author:

Ranftler Matthias^ORCID,Strasser-Weippl Kathrin

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://link.springer.com/article/10.1007/s12254-017-0348-y/fulltext.html

Reference32 articles.

1. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23.

2. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601.

3. Cabanillas F, Bodey GP, Burgess MA, Freireich EJ. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. Cancer Treat Rep. 1979;63(3):507–9.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

5. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2‑positive breast cancer. J Clin Oncol. 2011;29(4):351–4.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer;Biophysical Reviews;2018-01-11